In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Motif Bio plc (MTFB), with a price target of $5. The company’s shares closed yesterday at $1.61, close to its 52-week low of $1.54.
According to TipRanks.com, Byrnes is a 1-star analyst with an average return of -0.9% and a 25.0% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Flexion Therapeutics, and Heron Therapeutics.
Currently, the analyst consensus on Motif Bio plc is a Hold with an average price target of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.50 and a one-year low of $1.54. Currently, Motif Bio plc has an average volume of 171.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Motif Bio Plc is a clinical stage biopharmaceutical company which develops novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It pipeline of antibiotics includes iclaprim, and MTF-001, a preclinical program to design a dihydrofolate reductase inhibitor (DHFRi).
